| Return to quiescence of mouse neural stem cells by degradation of a proactivation protein N Urbán, DLC Van Den Berg, A Forget, J Andersen, JAA Demmers, ... Science 353 (6296), 292-295, 2016 | 238 | 2016 |
| The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation T Uziel, F Zindy, S Xie, Y Lee, A Forget, S Magdaleno, JE Rehg, ... Genes & development 19 (22), 2656-2667, 2005 | 188 | 2005 |
| Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma H Suzuki, SA Kumar, S Shuai, A Diaz-Navarro, A Gutierrez-Fernandez, ... Nature 574 (7780), 707-711, 2019 | 159 | 2019 |
| Aberrant ERBB4-SRC signaling as a hallmark of group 4 medulloblastoma revealed by integrative phosphoproteomic profiling A Forget, L Martignetti, S Puget, L Calzone, S Brabetz, D Picard, ... Cancer cell 34 (3), 379-395. e7, 2018 | 139 | 2018 |
| Germline elongator mutations in sonic hedgehog medulloblastoma SM Waszak, GW Robinson, BL Gudenas, KS Smith, A Forget, M Kojic, ... Nature 580 (7803), 396-401, 2020 | 128 | 2020 |
| Shh signaling protects Atoh1 from degradation mediated by the E3 ubiquitin ligase Huwe1 in neural precursors A Forget, L Bihannic, SM Cigna, C Lefevre, M Remke, M Barnat, S Dodier, ... Developmental cell 29 (6), 649-661, 2014 | 78 | 2014 |
| Atoh1 controls primary cilia formation to allow for SHH-triggered granule neuron progenitor proliferation CH Chang, M Zanini, H Shirvani, JS Cheng, H Yu, CH Feng, AL Mercier, ... Developmental Cell 48 (2), 184-199. e5, 2019 | 64 | 2019 |
| Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer KH Lin, JC Rutter, A Xie, B Pardieu, ET Winn, RD Bello, A Forget, ... Nature genetics 52 (4), 408-417, 2020 | 57 | 2020 |
| Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins G Boulay, M Dubuissez, C Van Rechem, A Forget, K Helin, O Ayrault, ... Journal of Biological Chemistry 287 (13), 10509-10524, 2012 | 53 | 2012 |
| Pathologic expression of MHC class II is driven by mitogen‐activated protein kinases I Martins, F Deshayes, F Baton, A Forget, I Ciechomska, K Sylla, F Aoudjit, ... European journal of immunology 37 (3), 788-797, 2007 | 44 | 2007 |
| ATOH1 promotes leptomeningeal dissemination and metastasis of sonic hedgehog subgroup medulloblastomas KB Grausam, SDR Dooyema, L Bihannic, H Premathilake, AS Morrissy, ... Cancer research 77 (14), 3766-3777, 2017 | 37 | 2017 |
| Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia B Pardieu, J Pasanisi, F Ling, R Dal Bello, J Penneroux, A Su, ... Leukemia 36 (6), 1585-1595, 2022 | 36 | 2022 |
| An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate J Zagozewski, GM Shahriary, LC Morrison, O Saulnier, M Stromecki, ... Nature Communications 11 (1), 3627, 2020 | 27 | 2020 |
| Differential post-transcriptional regulation of two Ink4 proteins, p18Ink4c and p19Ink4d A Forget, O Ayrault, W den Besten, ML Kuo, CJ Sherr, MF Roussel Cell Cycle 7 (23), 3737-3746, 2008 | 23 | 2008 |
| P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia KH Lin, JC Rutter, A Xie, ST Killarney, C Vaganay, C Benaksas, F Ling, ... Nature cancer 3 (7), 837-851, 2022 | 21 | 2022 |
| The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors J Bartl, M Zanini, F Bernardi, A Forget, L Blümel, J Talbot, D Picard, N Qin, ... Nature communications 13 (1), 4061, 2022 | 19 | 2022 |
| A review of computational approaches detecting microRNAs involved in cancer L Cantini, M Caselle, A Forget, A Zinovyev, E Barillot, L Martignetti Frontiers in Bioscience 22, 1774-1791, 2017 | 18 | 2017 |
| An autocrine ActivinB mechanism drives TGF β/Activin signaling in Group 3 medulloblastoma M Morabito, M Larcher, FMG Cavalli, C Foray, A Forget, L Mirabal‐Ortega, ... EMBO molecular medicine 11 (8), e9830, 2019 | 16 | 2019 |
| The folate cycle enzyme MTHFR is a critical regulator of cell response to MYC-targeting therapies A Su, F Ling, C Vaganay, G Sodaro, C Benaksas, R Dal Bello, A Forget, ... Cancer discovery 10 (12), 1894-1911, 2020 | 14 | 2020 |
| Target discovery for host-directed antiviral therapies: application of proteomics approaches M Cakir, K Obernier, A Forget, NJ Krogan Msystems 6 (5), 10.1128/msystems. 00388-21, 2021 | 12 | 2021 |
